Novo Challenges Order To Trim Prandin Patent
Novo Nordisk Inc. has appealed an injunction forcing the drugmaker to amend key use code in its patent for the diabetes treatment Prandin in litigation seeking to block Caraco Pharmaceutical Laboratories...To view the full article, register now.
Already a subscriber? Click here to view full article